A 582941partial agonist of α7 nicotinic acetylcholine receptors CAS# 848591-90-2 |
- PHT-427
Catalog No.:BCC2554
CAS No.:1191951-57-1
- AT7867 dihydrochloride
Catalog No.:BCC1378
CAS No.:1431697-86-7
- Perifosine
Catalog No.:BCC3673
CAS No.:157716-52-4
- TIC10
Catalog No.:BCC3906
CAS No.:41276-02-2
- A-674563
Catalog No.:BCC3903
CAS No.:552325-73-2
- CCT128930
Catalog No.:BCC3904
CAS No.:885499-61-6
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 848591-90-2 | SDF | Download SDF |
PubChem ID | 44190553 | Appearance | Powder |
Formula | C17H20N4 | M.Wt | 280.37 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in DMSO and to 50 mM in 1eq. HCl | ||
Chemical Name | (3aS,6aR)-2-methyl-5-(6-phenylpyridazin-3-yl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrole | ||
SMILES | CN1CC2CN(CC2C1)C3=NN=C(C=C3)C4=CC=CC=C4 | ||
Standard InChIKey | GTMRUYCIJSNXGB-GASCZTMLSA-N | ||
Standard InChI | InChI=1S/C17H20N4/c1-20-9-14-11-21(12-15(14)10-20)17-8-7-16(18-19-17)13-5-3-2-4-6-13/h2-8,14-15H,9-12H2,1H3/t14-,15+ | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Selective α7 nAChR partial agonist; exhibits high affinity for both rat and human α7 receptors (Ki values are 10.8 and 16.7 nM respectively). Displays ~15-fold selectivity for α7 over 5-HT3 receptors (Ki = 150 nM for 5-HT3). |
A 582941 Dilution Calculator
A 582941 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.5667 mL | 17.8336 mL | 35.6672 mL | 71.3343 mL | 89.1679 mL |
5 mM | 0.7133 mL | 3.5667 mL | 7.1334 mL | 14.2669 mL | 17.8336 mL |
10 mM | 0.3567 mL | 1.7834 mL | 3.5667 mL | 7.1334 mL | 8.9168 mL |
50 mM | 0.0713 mL | 0.3567 mL | 0.7133 mL | 1.4267 mL | 1.7834 mL |
100 mM | 0.0357 mL | 0.1783 mL | 0.3567 mL | 0.7133 mL | 0.8917 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
A 582941 is a highly selective partial agonist of α7 nicotinic acetylcholine receptors (nAChRs), with an EC50 value of 4260 nM to human α7 nAChRs [1].
nAChRs are a family of pentameric ligand-gated ion channels. They are derived from multiple α (α2-α10) and β (β2-β4) subunit genes. α7 nAChR receptor exhibits higher Ca2+ permeability than other nAChR combinations. These receptors modulate the release of multiple neurotransmitters, including acetylcholine (ACh), glutamate, and GABA [1].
In FLIPR, A 582941 did not activate recombinant heteromeric nAChRs (α4β2, α3β2, α3β4, or α4β4) according to Ca2+ dynamics results. In IMR-32 cells expressing native human α3β4 nAChRs, A 582941 did not produce an agonist effect (with an efficacy less than 20% at concentrations up to 100,000 nM). In Xenopus oocytes expressing an α9α10 nAChR construct, A 582941 at concentrations up to 100,000 nM did not evoke currents. With respect to nAChRs, A 582941 activated only the homomeric α7 subtype [1].
In a rat model of short-term memory based on olfactory cues, saline-treated adults used investigation times during the second session nearly equal to the first session, exhibiting little recognition of the juvenile. Treatment with A 582941 in adult rats resulted in a dose-related reduction in the exploration time during the second session compared with the first session, exhibiting improved recognition of the juvenile [1].
Reference:
[1]. Tietje KR, Anderson DJ, Bitner RS, et al. Preclinical Characterization of A-582941: A Novel α7 Neuronal Nicotinic Receptor Agonist with Broad Spectrum Cognition-Enhancing Properties. CNS neuroscience & therapeutics, 2008, 14(1): 65-82.
- Vasicinolone
Catalog No.:BCN4394
CAS No.:84847-50-7
- NCH 51
Catalog No.:BCC2422
CAS No.:848354-66-5
- AS 602801
Catalog No.:BCC1369
CAS No.:848344-36-5
- SSR128129E
Catalog No.:BCC4498
CAS No.:848318-25-2
- EX-527 R-enantiomer
Catalog No.:BCC5595
CAS No.:848193-69-1
- EX-527 S-enantiomer
Catalog No.:BCC5594
CAS No.:848193-68-0
- Alvelestat
Catalog No.:BCC4058
CAS No.:848141-11-7
- HKI 357
Catalog No.:BCC6046
CAS No.:848133-17-5
- 3,4-Dimethoxyphenyl beta-D-glucoside
Catalog No.:BCN4393
CAS No.:84812-00-0
- threo-1-(4-Hydroxy-3-methoxyphenyl)propane-1,2-diol
Catalog No.:BCN1331
CAS No.:848031-94-7
- 5-Epilithospermoside
Catalog No.:BCN4392
CAS No.:84799-31-5
- Lck Inhibitor
Catalog No.:BCC1689
CAS No.:847950-09-8
- P11
Catalog No.:BCC6275
CAS No.:848644-86-0
- Stigmasta-4,25-dien-3-one
Catalog No.:BCN4395
CAS No.:848669-08-9
- Stigmasta-4,22,25-trien-3-one
Catalog No.:BCN4396
CAS No.:848669-09-0
- BIIB021
Catalog No.:BCC2124
CAS No.:848695-25-0
- Gnetin D
Catalog No.:BCN3380
CAS No.:84870-53-1
- p-Hydroxyphenethyl trans-ferulate
Catalog No.:BCN3995
CAS No.:84873-15-4
- Pulsatilla camphor
Catalog No.:BCN8184
CAS No.:90921-11-2
- Betulinic acid 3β-O-alpha-L-rhamnopyranosyl-(1->2)-[β-D-glucopyranosyl-(1->4)]-alpha-L-arabinopyranoside
Catalog No.:BCC8303
CAS No.:848784-87-2
- AZD8931 (Sapitinib)
Catalog No.:BCC3734
CAS No.:848942-61-0
- UFP-101
Catalog No.:BCC5775
CAS No.:849024-68-6
- Floribundasaponin A
Catalog No.:BCN1330
CAS No.:37341-36-9
- Glaucogenin C mono-D-thevetoside
Catalog No.:BCN7089
CAS No.:849201-84-9
Profile of nicotinic acetylcholine receptor agonists ABT-594 and A-582941, with differential subtype selectivity, on delayed matching accuracy by young monkeys.[Pubmed:17706609]
Biochem Pharmacol. 2007 Oct 15;74(8):1202-11.
ABT-594 and A-582941 are high affinity neuronal nicotinic acetylcholine receptor agonists with differential selectivity for the alpha4beta2 and the alpha7 subtypes, respectively. This study was designed to determine whether either compound, like nicotine also possesses cognitive-enhancing ability. The compounds were administered by intramuscular injection to young adult Rhesus monkeys trained to perform two versions of a computer-assisted delayed matching-to-sample (DMTS) task. ABT-594 (0.115-3.7 microg/kg) significantly improved DMTS accuracies, shifting the retention curve (accuracy-delay relationship) to the right in a parallel fashion. DMTS accuracy also was maintained during the sessions initiated 24h after compound administration. Because task accuracy was improved during short delay trials, a separate study was performed in which non-predictable distractors were inserted within the DMTS format to impair accuracy. The 0.115 microg/kg dose of ABT-594 almost completely reversed distractor-impaired performance associated with short delay trials. The alpha7 nAChR agonist, A-582941 (1.14-38 microg/kg) also significantly improved DMTS accuracies. The compound produced a significant improvement during long delay trials. The effect was twice as robust for long delay as compared with short delay trials and A-582941 was not as effective as ABT-594 in improving short delay trial accuracy. A-582941 also failed to sustain task improvement during sessions run 24h after dosing. These data are consistent with the ability of subtype-preferring nicotinic receptor agonists to enhance specific components of working memory and cognitive function, and they suggest that differential subtype selectivity could result in varied pharmacological response profiles.
Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties.[Pubmed:18482100]
CNS Neurosci Ther. 2008 Spring;14(1):65-82.
Among the diverse sets of nicotinic acetylcholine receptors (nAChRs), the alpha7 subtype is highly expressed in the hippocampus and cortex and is thought to play important roles in a variety of cognitive processes. In this review, we describe the properties of a novel biaryl diamine alpha7 nAChR agonist, A-582941. A-582941 was found to exhibit high-affinity binding and partial agonism at alpha7 nAChRs, with acceptable pharmacokinetic properties and excellent distribution to the central nervous system (CNS). In vitro and in vivo studies indicated that A-582941 activates signaling pathways known to be involved in cognitive function such as ERK1/2 and CREB phosphorylation. A-582941 enhanced cognitive performance in behavioral models that capture domains of working memory, short-term recognition memory, memory consolidation, and sensory gating deficit. A-582941 exhibited a benign secondary pharmacodynamic and tolerability profile as assessed in a battery of assays of cardiovascular, gastrointestinal, and CNS function. The studies summarized in this review collectively provide preclinical validation that alpha7 nAChR agonism offers a mechanism with potential to improve cognitive deficits associated with various neurodegenerative and psychiatric disorders.
The selective alpha7 nicotinic acetylcholine receptor agonist A-582941 activates immediate early genes in limbic regions of the forebrain: Differential effects in the juvenile and adult rat.[Pubmed:18495359]
Neuroscience. 2008 Jun 23;154(2):741-53.
Due to the cognitive-enhancing properties of alpha7 nicotinic acetylcholine receptor (alpha7 nAChR) agonists, they have attracted interest for the treatment of cognitive disturbances in schizophrenia. Schizophrenia typically presents in late adolescence or early adulthood. It is therefore important to study whether alpha7 nAChR stimulation activates brain regions involved in cognition in juvenile as well as adult individuals. Here, we compared the effects of the novel and selective alpha7 nAChR agonist 2-methyl-5-(6-phenyl-pyridazin-3-yl)-octahydro-pyrrolo[3,4-c]pyrrole (A-582941) in the juvenile and adult rat forebrain using two markers, activity-regulated cytoskeleton-associated protein (Arc) and c-Fos, to map neuronal activity. Acute administration of A-582941 (1, 3, 10 mg/kg) induced a dose-dependent increase in Arc mRNA expression in the medial prefrontal cortex (mPFC) and the ventral/lateral orbitofrontal (VO/LO) cortex of juvenile, but not adult rats. This effect was mitigated by the alpha7 nAChR antagonist methyllycaconitine. A-582941 also increased c-Fos mRNA expression in the mPFC of juvenile, but not adult rats. Furthermore, A-582941 increased the number of Arc and c-Fos immunopositive cells in the mPFC, VO/LO, and shell of the nucleus accumbens, in both juvenile and adult rats. The A-582941-induced c-Fos protein expression was significantly greater in the mPFC and VO/LO of juvenile compared with adult rats. These data indicate that A-582941-induced alpha7 nAChR stimulation activates brain regions critically involved in working memory and attention. Furthermore, this effect is more pronounced in juvenile than adult rats, indicating that the juvenile forebrain is more responsive to alpha7 nAChR stimulation. This observation may be relevant in the treatment of juvenile-onset schizophrenia.
In vivo evaluation of alpha7 nicotinic acetylcholine receptor agonists [11C]A-582941 and [11C]A-844606 in mice and conscious monkeys.[Pubmed:20126539]
PLoS One. 2010 Feb 1;5(2):e8961.
BACKGROUND: The alpha7 nicotinic acetylcholine receptors (nAChRs) play an important role in the pathophysiology of neuropsychiatric diseases such as schizophrenia and Alzheimer's disease. The goal of this study was to evaluate the two carbon-11-labeled alpha7 nAChR agonists [(11)C]A-582941 and [(11)C]A-844606 for their potential as novel positron emission tomography (PET) tracers. METHODOLOGY/PRINCIPAL FINDINGS: The two tracers were synthesized by methylation of the corresponding desmethyl precursors using [(11)C]methyl triflate. Effects of receptor blockade in mice were determined by coinjection of either tracer along with a carrier or an excess amount of a selective alpha7 nAChR agonist (SSR180711). Metabolic stability was investigated using radio-HPLC. Dynamic PET scans were performed in conscious monkeys with/without SSR180711-treatment. [(11)C]A-582941 and [(11)C]A-844606 showed high uptake in the mouse brain. Most radioactive compounds in the brain were detected as an unchanged form. However, regional selectivity and selective receptor blockade were not clearly observed for either compound in the mouse brain. On the other hand, the total distribution volume of [(11)C]A-582941 and [(11)C]A-844606 was high in the hippocampus and thalamus but low in the cerebellum in the conscious monkey brain, and reduced by pretreatment with SSR180711. CONCLUSIONS/SIGNIFICANCE: A nonhuman primate study suggests that [(11)C]A-582941 and [(11)C]A-844606 would be potential PET ligands for imaging alpha7 nAChRs in the human brain.
[3H]A-585539 [(1S,4S)-2,2-dimethyl-5-(6-phenylpyridazin-3-yl)-5-aza-2-azoniabicyclo[2.2.1]hept ane], a novel high-affinity alpha7 neuronal nicotinic receptor agonist: radioligand binding characterization to rat and human brain.[Pubmed:17959745]
J Pharmacol Exp Ther. 2008 Jan;324(1):179-87.
Receptor binding was characterized for [(3)H](1S,4S)-2,2-dimethyl-5-(6-phenylpyridazin-3-yl)-5-aza-2-azoniabicyclo[2.2.1 ]heptane ([(3)H]A-585539), a selective high-affinity alpha7 nicotinic acetylcholine receptor (nAChR) agonist with rapid kinetics, low nonspecific binding, and high specific activity. At 4 degrees C, the association was monophasic and rapid (t((1/2)) = 8.0 min); dissociation was slower (t((1/2)) = 64.2 min). The K(d) in rat brain at 4 degrees C was 0.063 nM, whereas at 22 and 37 degrees C, the K(d) values were 0.188 and 0.95 nM, respectively. In contrast, the B(max) (34 fmol/mg protein) was unaffected by temperature. In human cortex, [(3)H]A-585539 bound with a K(d) of 0.066 nM and a B(max) of 5.8 fmol/mg protein at 4 degrees C, whereas under similar conditions, specific [(3)H]methyllycaconitine ([(3)H]MLA) binding was not measurable. A number of agonist and antagonist nAChR ligands displaced binding to rat brain membranes with rank order of affinity similar to that for [(3)H]MLA, and in general, a 5 to 10-fold higher affinity was observed for [(3)H]A-585539 binding. There was also a good correlation of K(i) values between [(3)H]A-585539 binding to rat brain and human cortex. The use of a alpha7/5-hydroxytryptamine type-3 chimera revealed that the N-terminal domain of alpha7 nAChR was sufficient to faithfully reproduce the pharmacology of [(3)H]A-585539 binding. Autoradiographic studies comparing [(3)H]A-585539 and [(125)I]alpha-bungarotoxin revealed a similar pattern of labeling in the rat. In summary, [(3)H]A-585539 was shown to have excellent binding characteristics in rat and human brain and represents the first high-affinity alpha7 agonist radioligand with utility in the characterization of this important nAChR subtype that is targeted toward ameliorating cognitive deficits underlying neuropsychiatric and neurodegenerative disorders.